| INTRODUCTION
One of the major emerging challenges in US health care has been the growing prevalence of opioid use disorder as shown by national epidemiologic surveys, 1 by the fact that US Healthcare consumers use more prescription opioids than all other high income countries put together, and by the rapidly increasing incidence of opioid overdose deaths. [2] [3] [4] Despite limited evidence of effectiveness, use of opioids for nonmalignant chronic pain has increased dramatically. 5, 6 Among patients served by the Veterans Health Administration (VHA), the annual prevalence of opioid prescribing is reported to have increased from 18.9% in fiscal year (FY) 2004 to 33.4% in FY2012 in less than a decade. 7 Expert guidelines recommend that chronic opioid therapy should be reserved for those suffering from intractable chronic pain not adequately managed with more conservative approaches (ie, cognitive and behavioural methods or rehabilitation) or interventional methods. [8] [9] [10] One group at special risk for expanding opioid use are patients with painful functional gastrointestinal disorders (FGIDs), unexplained GI symptoms with a predominant pain component such as irritable bowel syndrome (IBS) and functional dyspepsia (FD). Chronic opioid use may be particularly detrimental for this population, as chronic opioid exposure may actually worsen abdominal pain due to opioid induction of hyperalgesia, 11 and aggravation of IBS symptoms via alterations in intestinal transit and development of narcotic bowel syndrome. [12] [13] [14] IBS patients using prescription opioids report more severe GI symptoms, as well as poorer IBS-related and general
health-related quality of life. 15 FGID patients with multiple psychiatric comorbidities have previously been shown to be particularly susceptible to intolerance and discontinuation of GI treatment regimens. 16 With pain as a predominant symptom for FGID patients, abdominal-specific pain coupled with maladaptive behaviours and poor coping skills 17 may lead to extensive, unwarranted and potentially harmful opioid use.
Psychiatric and addictive comorbidities may serve as additional independent risk factors for opioid pain mediation use in these patients. 18 Nevertheless, opioid use in IBS and other GI patients with functional GI disorders has not been closely examined. 19 While preliminary data from one tertiary out-patient GI setting revealed that 43% (eg, dementia = 1; metastatic solid tumour = 6). This measure allows for stratification into "mild", "moderate" and "severe" illness categories, and is validated as a predictor of patient survival over a 10-year period. 21 Psychiatric diagnoses and trauma current during fiscal year 2012 included major depressive or generalised anxiety, abuse (ie, sexual, physical, emotional), bipolar affective, post-traumatic stress or personality disorders and were collected as potential mediators of opioid use. 15 History of a substance abuse diagnosis, or drug and/or alcohol dependence were also extracted as potential confounder variables.
Data on psychotropic medication prescription fills in fiscal year 2012 were obtained from VA Drug Benefit Management data files and were collapsed into several broad classes: antidepressants, antipsychotics, anticonvulsants/mood stabilisers, anxiolytics/sedative-hypnotics, stimulants and lithium.
| Medical encounters
Service use of emergency room visits, medical-surgical visits or any mental health in-patient or out-patient treatment were documented from the out-patient encounter file and the patient treatment file as potential mediating risk factors for opioid use.
| Statistical analysis
Analysis proceeded in several steps: first, bivariate analyses were conducted to compare opioid use and other sociodemographic, diagnostic and service use measures between the SGID and FGID groups. We used effect sizes rather than P-values for these compar- highlighted above. Subjects missing data were excluded from regression models. Finally, a separate analysis of FGID patients with and without documented opioid prescriptions was performed in order to determine the effect sizes associated with the potential factors associated with opioid use in this higher risk population. Table S1 . In terms of medical conditions, the prevalence of dementia, seizures and HIV were significantly higher in the FGID group compared to those with SGID. Fibromyalgia and somatic pain diagnoses were nearly 50% more common in FGID, but fell short of a priori thresholds for significance. The FGID group had a substantially greater numbers of emergency room visits, medical-surgical and total out-patient visits, with the level of emergency room encounters achieving significantly higher levels.
| RESULTS
Comparing psychiatric comorbidities, prevalence of bipolar and personality disorders was more prevalent in the FGID cohort. Traumatic abuse diagnoses were twice as common in the FGID patients, and psychiatric in-patient treatment similarly was higher in patients with unexplained GI symptoms. Antidepressant prescription and other psychotropic medication fills were also greater in the FGID group, but fell short of significance.
| Stepwise multivariate modelling of factors associated with opioid use among veterans with GI symptoms
Compared to veterans with a structural GI diagnosis (SGID), patients with unexplained GI symptoms (FGID) had a 40% higher likelihood of receiving an opioid prescription ( (Table S2 ).
| DISCUSSION
In this study, we found substantial rates of opioid prescription use among US veterans with recent gastrointestinal diagnoses, with nearly one in three such veterans having received an opioid medication prescription during the 12-month study period, and an average A recent Veterans Health Administration (VHA) data suggested a 74% increase in the annual prevalence of opioid prescriptions in less than a decade. 7 Trends of increasing opioid prescription use similarly have been identified in the private sector 22 and in Medicare recipients. 23 While opioid medications undeniably are essential to the short-term management of moderate to severe forms of acute pain, and perhaps for the control of select forms of severe, chronic pain (eg, cancer-related pain), the role of these medications in unexplained or functional GI disorders, and especially those without manifest structural disease, should remain quite limited. A study by Dorn et al reported a doubling in out-patient opioid prescriptions for chronic abdominal pain from 1997 to 2008. 20 We observed that 1/3 of veterans with functional GI diagnoses examined obtained at least one opioid prescription during the study period, 1.4 times the proportion with structural GI disease receiving an opioid medication.
Even with short-term use, "opioid bowel dysfunction" manifested by nausea and vomiting, bloating/distention and constipation are common, making opioids an ill-advised, if not contraindicated, pain management option in patients with GI symptoms and especially Consistent with previous research, FGID patients in this study were much more likely to have psychiatric diagnoses (major depression, anxiety disorders and PTSD) compared to veterans in the structural SGID cohort. 27 Negative emotional states and comorbid psychiatric illness such as generalised anxiety, major depressive disorder and symptoms of somatisation are associated with more severe bowel symptoms. [28] [29] [30] In our multivariate model, we found a substantial portion of the risk of opioid prescription use in patients with unexplained GI symptoms seemingly mediated by comorbid psychiatric diagnoses. More frequent healthcare encounters, emergency room visits in particular, also mediated opioid prescriptions in this veteran population. When present, these factors should prompt the physician to exercise even greater caution in avoiding inappropriate opioid prescriptions.
This study represents one of the first studies to examine opioid prescriptions for veterans with GI diagnoses at a national level using a comprehensive list of diagnostic codes. The integrated VA electronic medical record and Drug Benefit Management data are quite robust, minimising the likelihood of incomplete clinical or prescription data. Rigorous statistical methodology was applied in order to minimise the risk of type I errors in our hypothesis testing, and we were comprehensive in our attempts to control for potentially important demographic and medical factors as covariates in our multivariate analyses. Several study limitations warrant mention. As with all VA-based studies, the population is predominantly male and has a unique socioeconomic and education profile relative to the general population. 31 Veterans, especially those who use VHA services have lower incomes, greater rates of disability and higher rates of psychiatric diagnoses compared to their civilian counterparts, even prior to combat experience. 32, 33 While these observations may not entirely generalise to patients in other non-VA healthcare systems, this study population presents an opportunity to examine opioid use among a more demographically and socioeconomically homogeneous population. In a recent review of our university GI practice, a remarkably similar rate of current opioid pain medication use (43.1%) was documented among irritable bowel syndrome referrals. 34 All of the data presented in the current study were based on administrative records, such that the accuracy of diagnoses could not be independently validated. Additionally, the data queried did not allow us to examine symptom experiences qualitatively (eg, pain severity, duration and impaction on well-being). While overlapping functional and structural GI disorders may be recognised in the same patient clinically, our study design required us to dichotomise patients into either the unexplained GI symptoms/functional GI or structural GI disorder group. Similarly, unexplained GI symptoms during the study period might ultimately be ascribed to a structural GI diagnosis. This kind of diagnosis overlap and misclassification might have led to underestimation of the effects sizes attributed to the specific class of GI diagnoses. Also, we were unable to definitively determine whether the opioid prescriptions provided to patients were specifically intended to address GI-related pain symptoms, as some could well have been used to address acute pain related to accidents or surgery. This concern was tempered by the observation that modelling a comprehensive list of potentially confounding non-GI medical diagnoses, which might also have been indications for opioid prescriptions, only modestly impacted the effect size of GI diagnosis as a predictor of opioid prescription use. We only examined VA pharmacy data, and it is likely that some of the patients obtained additional opiate prescriptions from outside the system, resulting in an underestimation of total opioid use among subjects in this study. For example, previous work has suggested that around 13% of veterans with noncancer pain obtain overlapping prescriptions using their non-VA Medicare benefits. 35 Finally, we were unable to determine either the specialty focus of the provider (eg, internist, gastroenterologist) or the specific clinical origin of the opioid prescription (eg, emergency room, out-patient setting)
T A B L E 3 Significant sociodemographic and clinical characteristics differences in unexplained GI symptom group based on receipt of opioid prescriptions from the available data. Future studies will be necessary to provide further insight into these prescriber characteristics, and to understand at a more granular level the opioid pain medications use patterns (eg, defined daily doses) among patients with GI diagnoses.
In conclusion, opioid pain medications commonly are prescribed to veterans with gastrointestinal diagnoses, even more so among those with unexplained GI symptoms and functional GI diagnoses.
This latter subgroup of GI patients may be particularly susceptible to the untoward effects of opioid pain medication on intestinal motility and visceral hyperalgesia. Psychiatric comorbidity, psychotropic prescriptions and increased emergency room encounters were notable correlates, and potential drivers of opioid use in this patient population. It is critical that physicians recognise this distinctive risk among some GI patients, and by identifying higher risk patients, minimise harmful opioid use in GI patients without well-characterised structural disorders.
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